Gastrointestinal OTC Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the gastrointestinal OTC drugs market size was valued at USD 46.89 billion in 2025 and is estimated to grow from USD 48.88 billion in 2026 to reach USD 60.19 billion by 2031, at a CAGR of 4.25% during the forecast period (2026-2031).

Global Gastrointestinal OTC Drugs Market Trends and Insights

Rising Burden of Heartburn, Constipation, and Acute Gastrointestinal Symptoms

The gastrointestinal OTC drugs market benefited from the recurring prevalence of heartburn, constipation, and acute digestive symptoms, which consumers commonly managed without prescriptions. Dietary habits, sedentary lifestyles, aging populations, and obesity sustained demand for acid-relief and constipation products, with obesity linked to both GERD and constipation. Heartburn and indigestion supported demand for low-cost antacids and acid-suppression products, while low fiber intake and limited activity drove laxative demand. In 2026, a systematic review reported gastrointestinal adverse effects in 50%-60% of patients initiating GLP-1 receptor agonists, supporting demand for antacids, anti-diarrheals, fiber products, and anti-emetics.

OTC Switches and Broader Access to Acid-Control Therapies

The gastrointestinal OTC drugs market gained momentum from prescription-to-OTC switches for acid-control therapies. Japan approved the Rx-to-OTC switch of Pariet S, a rabeprazole product, in 2025, and Eisai subsequently launched it as Japan's first proton pump inhibitor to transition from prescription status to OTC availability. In the United States, the FDA's Additional Condition for Nonprescription Use rule became effective on May 27, 2025, enabling additional conditions such as technology-assisted processes or pharmacist consultation when labeling alone was insufficient. These developments expanded consumer access but also increased the need for pharmacist guidance, while creating greater price competition from retailers and generic suppliers.

Safety Concerns and Misuse of Long-Term Acid Suppression

Safety concerns limited the repeat use of acid-suppression products without appropriate guidance. Reviews published in 2025 and 2026 discussed potential associations between long-term proton pump inhibitor use and several health outcomes, although causal relationships remained difficult to establish in some cases. These concerns made pharmacists and healthcare providers more cautious about repeated self-treatment. The gastrointestinal OTC drugs market needed to balance accessibility with clear use instructions, referral guidance, and appropriate labeling. Community pharmacies also helped consumers distinguish occasional heartburn from symptoms requiring medical assessment, particularly as more prescription-grade therapies became available over the counter.

Other drivers and restraints analyzed in the detailed report include:

1. E-Commerce and Omnichannel Availability of Digestive-Health Products
2. GLP-1-Associated Gastrointestinal Symptom Management
3. Retailer Private-Label and Price-Led Substitution

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Antacids held 28.67% of the gastrointestinal OTC drugs market share by drug class in 2025. Their leading position reflected broad availability, affordable pricing, and rapid relief for occasional symptoms within 1-5 minutes. Laxatives, antidiarrheals, antiemetics, and H2 receptor antagonists, including famotidine- and cimetidine-based products, also maintained demand across self-managed gastrointestinal conditions.

Proton pump inhibitors (PPIs) are forecast to record the highest growth at a CAGR of 5.67% from 2026 to 2031. Japan's 2025 switch approvals and the U.S. ACNU pathway supported access to PPIs for recurring reflux management. While PPIs provide sustained acid suppression, safety concerns reinforce the need for pharmacist guidance and support demand for digestive enzymes, simethicone, and specialty products.

Heartburn and indigestion held 32.44% of the indication-based market share in 2025. The gastrointestinal OTC drugs market addressed short-term post-meal discomfort and recurring symptom management, with antacids commonly used for immediate relief. Constipation, diarrhea, nausea, vomiting, gas, flatulence, and bloating also supported demand for self-medication products, including simethicone and probiotic-oriented offerings.

GERD is forecast to grow at a CAGR of 6.23% from 2026 to 2031. This segment reflects demand for sustained acid control, leading consumers to prefer PPIs and H2 receptor antagonists over traditional antacids. Regulatory switches improved pharmacy access; however, persistent symptoms require pharmacist guidance and may need medical evaluation.

Complete Report Scope:

• By Drug Class
  • Antacids
  • Laxatives
  • Anti-Diarrheals
  • Anti-Emetics
  • Proton Pump Inhibitors
  • H2-Receptor Antagonists
  • Digestive Enzymes, Simethicone, and Other Products
• By Indication
  • Heartburn and Indigestion
  • Gastroesophageal Reflux Disease
  • Constipation
  • Diarrhea
  • Nausea and Vomiting
  • Motion Sickness
  • Gas, Flatulence, and Bloating
  • Others
• By Formulation
  • Tablets
  • Chewable Tablets and Gummies
  • Capsules and Softgels
  • Liquids and Suspensions
  • Effervescent Granules and Tablets
  • Fast-Dissolve Strips and Powders
  • Others
• By Route of Administration
  • Oral
  • Topical
  • Rectal
• By Distribution Channel
  • Retail Pharmacies
  • Hospital Pharmacies
  • Supermarkets and Hypermarkets
  • Online Pharmacies
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 40.44% of the gastrointestinal OTC drugs market share in 2025, supported by high OTC healthcare spending and mature retail pharmacy infrastructure. The FDA's ACNU rule, effective in May 2025, supported nonprescription access for products requiring additional conditions for safe use. This framework could support future switches for acid-control and anti-diarrheal products. Canada aligned closely with U.S. regulatory standards, while Mexico followed the COFEPRIS framework.

Europe remained the second-largest regional market, although country-specific requirements slowed coordinated product launches. Community pharmacies played a key advisory role in France, Italy, and Spain by supporting product selection and referrals for persistent symptoms. Private-label competition remained significant in the United Kingdom and Germany, where store brands occupied substantial supermarket and pharmacy shelf space. The region combined strong self-care demand with a focus on pricing and professional guidance.

Asia-Pacific is forecast to grow at a CAGR of 6.98% from 2026 to 2031. China held 36.05% of the Asia-Pacific OTC drugs market in 2025, supported by urban e-commerce access, while India is expected to register the highest sub-regional CAGR. Bayer expanded Alka-Seltzer in India across 100,000 retail outlets, targeting 100 million households over four years. South America, the Middle East, and Africa offer long-term potential through expanding pharmacy networks, self-care regulations, and digital retail access.

1. Abbott Laboratories
2. Alkem Laboratories Limited
3. Bayer
4. Boehringer Ingelheim
5. Cipla
6. Dr. Reddy's Laboratories
7. Haleon plc
8. Johnson & Johnson
9. Kenvue Inc.
10. Nestle S.A.
11. Perrigo Company
12. Pfizer
13. Prestige Consumer Healthcare
14. Reckitt Benckiser Group
15. Sanofi
16. Sun Pharmaceuticals Industries
17. Takeda Pharmaceuticals
18. Teva Pharmaceutical Industries
19. Procter & Gamble
20. Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support